Benjamin O, Goyal A, Lappin SL (2018) Disease modifying anti-rheumatic drugs (DMARD). In: StatPearls [Internet]. StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK507863/. Updated 3 July 2023

Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad A (2024a) Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open 10(2):e003912. https://doi.org/10.1136/rmdopen-2023-003912

Article  PubMed  PubMed Central  Google Scholar 

Calabrese LH, Abud-Mendoza C, Lindsey SM, Lee S-H, Tatulych S, Takiya L, Iikuni N, Soma K, Luo Z, Fleischmann R (2020) Live Zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase IIIb/IV randomized study. Arthritis Care Res (Hoboken) 72(3):353–359. https://doi.org/10.1002/acr.24010

Article  PubMed  Google Scholar 

Choi SR, Shin A, Ha Y-J, Lee YJ, Lee EB, Kang EH (2023) Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther 25(1):129. https://doi.org/10.1186/s13075-023-03111-w

Article  PubMed  PubMed Central  Google Scholar 

Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80(3):304–311. https://doi.org/10.1136/annrheumdis-2020-218510

Article  PubMed  Google Scholar 

Curtis JR, Yamaoka K, Chen Y-H, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gómez-Reino JJ (2023) Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis 82(3):331–343. https://doi.org/10.1136/ard-2022-222543

Article  PubMed  Google Scholar 

Deakin C, De Stavola B, Littlejohn G, Griffiths H, Ciciriello S, Youssef P, Mathers D, Bird P, Smith T, Osullivan C, Freeman T, Segelov D, Hoffman D, Seaman S (2022) Emulating a target trial of adalimumab versus tofacitinib in patients with rheumatoid arthritis: a comparative effectiveness analysis using the opal real-world dataset. Ann Rheum Dis 81(Suppl 1):624.622–625. https://doi.org/10.1136/annrheumdis-2022-eular.2515

Deakin CT, De Stavola BL, Littlejohn G, Griffiths H, Ciciriello S, Youssef P, Mathers D, Bird P, Smith T, O’Sullivan C, Freeman T, Segelov D, Hoffman D, Seaman SR (2023) Comparative effectiveness of adalimumab vs tofacitinib in patients with rheumatoid arthritis in Australia. JAMA Netw Open 6(6):e2320851. https://doi.org/10.1001/jamanetworkopen.2023.20851

Article  PubMed  PubMed Central  Google Scholar 

Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, Swierkot J, Khan N, Bu X, Li Y, Song I-H (2022a) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open 8(1):e002012. https://doi.org/10.1136/rmdopen-2021-002012

Article  PubMed  PubMed Central  Google Scholar 

Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song I-H (2019) Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 78(11):1454–1462. https://doi.org/10.1136/annrheumdis-2019-215764

Article  PubMed  Google Scholar 

Gazitt T, Lood C, Elkon KB (2016) Citrullination in rheumatoid arthritis—a process promoted by neutrophil lysis? Rambam Maimonides Med J. https://doi.org/10.5041/rmmj.10254

Article  PubMed  PubMed Central  Google Scholar 

Genovese MC, van Vollenhoven RF, Wilkinson B, Wang L, Zwillich SH, Gruben D, Biswas P, Riese R, Takiya L, Jones TV (2016) Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther 18:145–145. https://doi.org/10.1186/s13075-016-1049-3

Article  PubMed  PubMed Central  Google Scholar 

Giles JT (2019) Extra-articular manifestations and comorbidity in rheumatoid arthritis: potential impact of pre-rheumatoid arthritis prevention. Clin Ther 41(7):1246–1255. https://doi.org/10.1016/j.clinthera.2019.04.018

Article  PubMed  Google Scholar 

Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6:15. https://doi.org/10.1038/s41413-018-0016-9

Article  PubMed  PubMed Central  Google Scholar 

Harrington R, Al Nokhatha SA, Conway R (2020) JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res 13:519–531. https://doi.org/10.2147/jir.s219586

Article  PubMed  PubMed Central  Google Scholar 

Harrington R, Harkins P, Conway R (2023) Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib. J Clin Med 12(20):6690

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

Article  PubMed  PubMed Central  Google Scholar 

Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maśliński W (2017) The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent Eur J Immunol 42(4):390–398. https://doi.org/10.5114/ceji.2017.72807

Article  PubMed  PubMed Central  Google Scholar 

Lassere MN, Rappo J, Portek IJ, Sturgess A, Edmonds JP (2013) How many life years are lost in patients with rheumatoid arthritis? Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. Intern Med J 43(1):66–72. https://doi.org/10.1111/j.1445-5994.2012.02727.x

Article  PubMed  Google Scholar 

Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, Cordtz R, De Cock D, Dreyer L, Elkayam O, Hauge EM, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Kristianslund EK, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Strangfeld A, Verschueren P, Courvoisier DS, Finckh A (2022) Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the “JAK-pot” collaboration. Ann Rheum Dis 81(10):1358–1366. https://doi.org/10.1136/annrheumdis-2022-222586

Article  PubMed  Google Scholar 

Ma X, Xu S (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1(2):177–184. https://doi.org/10.3892/br.2012.42

Article  PubMed  Google Scholar 

Mysler E, Tanaka Y, Kavanaugh A, Aletaha D, Taylor PC, Song I-H, Shaw T, Song Y, DeMasi R, Ali M, Fleischmann R (2023) Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford) 62(5):1804–1813. https://doi.org/10.1093/rheumatology/keac477

Article  PubMed  Google Scholar 

Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, Gruben D, Kwok K, Wang C, Hsu M-A, Maniccia A (2020) Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open 6(1):e001042. https://doi.org/10.1136/rmdopen-2019-001042

Article  PubMed  PubMed Central  Google Scholar 

Ostör AJ (2008) Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol 27(11):1343–1353. https://doi.org/10.1007/s10067-008-0964-3

Article  PubMed  Google Scholar 

Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG (2017) Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Dev Ther 11:1593–1603. https://doi.org/10.2147/dddt.s100302

Article  Google Scholar 

Rendas-Baum R, Kosinski M, Singh A, Mebus CA, Wilkinson BE, Wallenstein GV (2017) Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials. Rheumatology (Oxford) 56(8):1386–1394. https://doi.org/10.1093/rheumatology/kex087

Article  PubMed  Google Scholar 

Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R (2019) Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open 5(2):e001040. https://doi.org/10.1136/rmdopen-2019-001040

Article  PubMed  PubMed Central  Google Scholar 

Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song I-H, Enejosa J, Schlacher C, Song Y, Fleischmann R (2021) Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford) 60(12):5583–5594. https://doi.org/10.1093/rheumatology/keab158

Article  PubMed  Google Scholar